These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 39202480

  • 21. Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients.
    Li T, Wilcox CS, Lipkowitz MS, Gordon-Cappitelli J, Dragoi S.
    Am J Nephrol; 2019; 50(6):411-421. PubMed ID: 31630148
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial.
    Htay H, Cho Y, Pascoe EM, Darssan D, Hawley C, Johnson DW, balANZ trial investigators.
    Perit Dial Int; 2017; 37(3):283-289. PubMed ID: 27935537
    [Abstract] [Full Text] [Related]

  • 25. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
    Mende CW.
    Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
    [Abstract] [Full Text] [Related]

  • 26. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2.
    Zhou Y, Fan J, Zheng C, Yin P, Wu H, Li X, Luo N, Yu X, Chen C.
    Biomed Pharmacother; 2019 Jan; 109():1327-1338. PubMed ID: 30551383
    [Abstract] [Full Text] [Related]

  • 27. SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
    Balzer MS, Rong S, Nordlohne J, Zemtsovski JD, Schmidt S, Stapel B, Bartosova M, von Vietinghoff S, Haller H, Schmitt CP, Shushakova N.
    Biomolecules; 2020 Nov 19; 10(11):. PubMed ID: 33228017
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA.
    Cardiovasc Diabetol; 2019 Aug 05; 18(1):99. PubMed ID: 31382965
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T, DAPA-CKD Trial Committees and Investigators.
    Lancet Diabetes Endocrinol; 2021 Nov 05; 9(11):743-754. PubMed ID: 34619108
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Lower Serum Albumin Level Is Associated With an Increased Risk for Loss of Residual Kidney Function in Patients Receiving Peritoneal Dialysis.
    Yamada S, Kawai Y, Tsuneyoshi S, Tsujikawa H, Arase H, Yoshida H, Tsuruya K, Nakano T, Kitazono T.
    Ther Apher Dial; 2020 Feb 05; 24(1):72-80. PubMed ID: 31125508
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD.
    JAMA Cardiol; 2021 Jul 01; 6(7):801-810. PubMed ID: 33851953
    [Abstract] [Full Text] [Related]

  • 38. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A.
    Adv Ther; 2021 May 01; 38(5):2201-2212. PubMed ID: 33860925
    [Abstract] [Full Text] [Related]

  • 39. The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients.
    Borkum M, Jamal A, Suneet Singh R, Levin A.
    Perit Dial Int; 2023 Mar 01; 43(2):139-144. PubMed ID: 35491897
    [Abstract] [Full Text] [Related]

  • 40. Association of Lower Serum Bilirubin With Loss of Residual Kidney Function in Peritoneal Dialysis Patients.
    Tsujikawa H, Tanaka S, Hara M, Kawai Y, Matsukuma Y, Torisu K, Nakano T, Tsuruya K, Kitazono T.
    Ther Apher Dial; 2020 Apr 01; 24(2):202-207. PubMed ID: 31207066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.